In the June 2024 issue of Hepatology Communications in the article by Bajaj et al., “Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence”, the term “rifaximin” was spelled incorrectly throughout Figure 1. That error has now been fixed.
REFERENCE
- 1.Sanyal AJ, Kowdley KV, Reau NS, Pyrsopoulos NT, Allen C, Heimanson Z, et al. Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence. Hepatol Commun. 2024;8:e0436. doi: 10.1097/HC9.0000000000000436 [DOI] [PMC free article] [PubMed] [Google Scholar]